NextCure (FRA:2US) Current Accrued Expense : €2.78 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is NextCure Current Accrued Expense?

NextCure's Current Accrued Expense for the quarter that ended in Mar. 2025 was €2.78 Mil.

NextCure's quarterly Current Accrued Expense declined from Sep. 2024 (€4.56 Mil) to Dec. 2024 (€3.15 Mil) and declined from Dec. 2024 (€3.15 Mil) to Mar. 2025 (€2.78 Mil).

NextCure's annual Current Accrued Expense declined from Dec. 2022 (€4.00 Mil) to Dec. 2023 (€3.47 Mil) and declined from Dec. 2023 (€3.47 Mil) to Dec. 2024 (€3.15 Mil).

NextCure Current Accrued Expense Historical Data

The historical data trend for NextCure's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCure Current Accrued Expense Chart

NextCure Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

3.79

3.94

4.00

3.47

3.15

NextCure Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															4.68	5.35	4.56	3.15	2.78

NextCure Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

NextCure Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of NextCure's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

NXTC:USA

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Headlines

No Headlines